Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846989 · ClinicalTrials.gov registry record · Phase 1
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT00846989: Completed Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Novartis Pharmaceuticals.
NCT00846989 is a Phase 1 study of Glaucoma and Ocular Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 276 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846989, a Phase 1 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
Conditions Studied
Interventions
- DRUG Latanoprost
- DRUG RKI983A
Study Locations (20)
California
- Novartis Investigative Site - Artesia
- Novartis Investigative Site - Inglewood
- Novartis Investigative Site - La Jolla
- Novartis Investigative Site - Poway
- Novartis Investigative Site - Stockton
Georgia
- Novartis Investigative Site - Atlanta
- Novartis Investigative Site - Morrow
- Novartis Investigative Site - Roswell
New York
- Novartis Investigative Site - Bethpage
- Novartis Investigative Site - Lynbrook
- Novartis Investigative Site - Rochester
Connecticut
- Novartis Investigative Site - Danbury
Hawaii
- Novartis Investigative Site - Kaneohe
Kansas
- Novartis Investigative Site - Topeka
Kentucky
- Novartis Investigative Site - Louisville
Louisiana
- Novartis Investigative Site - Bossier City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00846989 record still lists
NCT00846989 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Latanoprost is the first listed.
NCT00846989 names 20 study sites across 12 states, led by California, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT00846989 about?
NCT00846989 is a clinical study titled "Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension". This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
What is the current status of trial NCT00846989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2009-01. Estimated completion is 2009-04.
What conditions does trial NCT00846989 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT00846989?
The interventions under investigation include: Latanoprost (DRUG), RKI983A (DRUG).
Who is sponsoring clinical trial NCT00846989?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00846989 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Hawaii, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00846989's enrollment target sits among peer trials
276 19th of 92 higher than 74 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia